Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 12
GLP-1 drugs and antipsychotic care
A 2026 meta-analysis pooled eight trials of GLP-1 receptor agonists for cardiometabolic outcomes in antipsychotic-treated patients.
GLP-1 and pulmonary hypertension
A new review finds mechanistic and preclinical signals for GLP-1 medicines in pulmonary hypertension, but no established clinical efficacy.
Lower-dose semaglutide: record says
A new article title raises a lower-dose semaglutide question, but the available record does not yet provide methods or results.
Obesity-Associated OA Explained
A new review separates mechanical loading, metabolic signaling, and obesity memory in osteoarthritis, while keeping treatment claims in perspective.
Retatrutide and Cagrilintide in Rats
A new rat study tested cagrilintide with retatrutide. Here is what the animal data found and what it cannot establish for people.
Retatrutide testing: plasma, not urine
A new LC-HRMS study found retatrutide signals in plasma but not urine. Here is what that result means, and what it does not.
SELECT frailty analysis of semaglutide
A post hoc SELECT analysis examined whether baseline frailty changed semaglutide outcomes in adults with cardiovascular disease and overweight or obesity.
Tirzepatide and Urology Evidence
A 2026 review links GLP-1 medicines to urology questions. Here is what tirzepatide evidence shows, and where the gaps remain.
WIN-IND: Intas Semaglutide Trial
WIN-IND found similar 24-week HbA1c changes with Intas and reference semaglutide, but its non-inferiority rule needs clarification.
GLP-1 Drugs and Biological Aging
A 2026 review examines whether GLP-1 receptor agonists could support healthier aging and where the evidence still stops short.
GLP-1 and PCOS: Reading a New Letter
A 2026 letter raises a possible GLP-1 and PCOS association, but genetic and reporting evidence cannot establish cause or guide treatment.
GLP-1 Psychiatric Safety in Adolescents
A 2026 cohort study found no increased recorded psychiatric risk among adolescents using GLP-1 or dual GIP/GLP-1 medicines.